Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
The role of tumour–stromal interactions in modifying drug response: challenges and opportunities
DW McMillin, JM Negri, CS Mitsiades - Nature reviews Drug discovery, 2013 - nature.com
The role of stromal cells and the tumour microenvironment in general in modulating tumour
sensitivity is increasingly becoming a key consideration for the development of active …
sensitivity is increasingly becoming a key consideration for the development of active …
Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors
AB Patel, T O'Hare… - Hematology/Oncology …, 2017 - hemonc.theclinics.com
Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …
Linking the future of anticancer metal-complexes to the therapy of tumour metastases
Cancer chemotherapy is almost always applied to patients with one or more diagnosed
metastases and is expected to impact these lesions, thus providing significant benefits to the …
metastases and is expected to impact these lesions, thus providing significant benefits to the …
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signaling
B Zhang, M Li, T McDonald… - Blood, The Journal …, 2013 - ashpublications.org
Tyrosine kinase inhibitors (TKIs) are highly effective in treatment of chronic myeloid
leukemia (CML) but do not eliminate leukemia stem cells (LSCs), which remain a potential …
leukemia (CML) but do not eliminate leukemia stem cells (LSCs), which remain a potential …
Myeloid malignancies and the microenvironment
C Korn, S Méndez-Ferrer - Blood, The Journal of the American …, 2017 - ashpublications.org
Research in the last few years has revealed a sophisticated interaction network between
multiple bone marrow cells that regulate different hematopoietic stem cell (HSC) properties …
multiple bone marrow cells that regulate different hematopoietic stem cell (HSC) properties …
BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia
F Loscocco, G Visani, S Galimberti, A Curti… - Frontiers in …, 2019 - frontiersin.org
Not all chronic myeloid leukemia (CML) patients are cured with tyrosine kinase inhibitors
(TKIs), and a proportion of them develop resistance. Recently, continuous BCR-ABL gene …
(TKIs), and a proportion of them develop resistance. Recently, continuous BCR-ABL gene …
Stat3 signaling in acute myeloid leukemia: ligand-dependent and-independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor
MS Redell, MJ Ruiz, TA Alonzo… - Blood, The Journal …, 2011 - ashpublications.org
Acute myeloid leukemia (AML) is an aggressive malignancy with a relapse rate approaching
50%, despite aggressive chemotherapy. New therapies for AML are targeted at signal …
50%, despite aggressive chemotherapy. New therapies for AML are targeted at signal …
[HTML][HTML] A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition
DJ Goff, A Sadarangani, HJ Chun, CL Barrett… - Cell stem cell, 2013 - cell.com
Leukemia stem cells (LSCs) play a pivotal role in the resistance of chronic myeloid leukemia
(CML) to tyrosine kinase inhibitors (TKIs) and its progression to blast crisis (BC), in part …
(CML) to tyrosine kinase inhibitors (TKIs) and its progression to blast crisis (BC), in part …
Tunneling nanotube-mediated intercellular vesicle and protein transfer in the stroma-provided imatinib resistance in chronic myeloid leukemia cells
MD Kolba, W Dudka, M Zaręba-Kozioł, A Kominek… - Cell death & …, 2019 - nature.com
Intercellular communication within the bone marrow niche significantly promotes
leukemogenesis and provides protection of leukemic cells from therapy. Secreted factors …
leukemogenesis and provides protection of leukemic cells from therapy. Secreted factors …